Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Herlinde Dumez

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
The New England Journal of Medicine|April 13, 2007
Sunitinib and hypothyroidismPascal Wolter, Herlinde Dumez, Patrick Schöffski
Critical Reviews in Clinical Laboratory Sciences|July 24, 2004
Human red blood cells: rheological aspects, uptake, and release of cytotoxic drugsHerlinde Dumez, Walter H Reinhart, Gunther Guetens, et al.
Onkologie|March 31, 2007
Recurrent low- to intermediate-grade chondrosarcoma of the thumb with lung metastases: an objective response to trofosfamidePhilip R Debruyne, Herlinde Dumez, Wim Demey, et al.
Anti-Cancer Drugs|December 13, 2006
A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancerHerlinde Dumez, Helen Gall, Renaud Capdeville, et al.
European Journal of Cancer (Oxford, England : 1990)|October 23, 2017
First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumoursPatrick Schöffski, Jean-Pierre Delord, Etienne Brain, et al.
European Urology Oncology|April 25, 2024
Progression-directed Therapy in Oligoprogressive Castration-resistant Prostate Cancer: Final Results from the Prospective, Single-arm, Phase 2 MEDCARE TrialKato Rans, Steven Joniau, Charlien Berghen, et al.
Anti-Cancer Drugs|April 2, 2004
Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II studyRandal D'hondt, Robert Paridaens, Hans Wildiers, et al.
Frontiers in Oncology|October 9, 2023
Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patientsAlexander Giesen, Loïc Baekelandt, Wout Devlies, et al.
Anti-Cancer Drugs|March 20, 2002
Altered irinotecan metabolism in a patient receiving phenytoinRon H J Mathijssen, Alex Sparreboom, Herlinde Dumez, et al.
Expert Opinion on Pharmacotherapy|June 4, 2008
Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcomaPatrick Schöffski, Herlinde Dumez, Pascal Wolter, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
The New England Journal of Medicine|April 13, 2007
Sunitinib and hypothyroidismPascal Wolter, Herlinde Dumez, Patrick Schöffski
Critical Reviews in Clinical Laboratory Sciences|July 24, 2004
Human red blood cells: rheological aspects, uptake, and release of cytotoxic drugsHerlinde Dumez, Walter H Reinhart, Gunther Guetens, et al.
Onkologie|March 31, 2007
Recurrent low- to intermediate-grade chondrosarcoma of the thumb with lung metastases: an objective response to trofosfamidePhilip R Debruyne, Herlinde Dumez, Wim Demey, et al.
Anti-Cancer Drugs|December 13, 2006
A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancerHerlinde Dumez, Helen Gall, Renaud Capdeville, et al.
European Journal of Cancer (Oxford, England : 1990)|October 23, 2017
First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumoursPatrick Schöffski, Jean-Pierre Delord, Etienne Brain, et al.
European Urology Oncology|April 25, 2024
Progression-directed Therapy in Oligoprogressive Castration-resistant Prostate Cancer: Final Results from the Prospective, Single-arm, Phase 2 MEDCARE TrialKato Rans, Steven Joniau, Charlien Berghen, et al.
Anti-Cancer Drugs|April 2, 2004
Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II studyRandal D'hondt, Robert Paridaens, Hans Wildiers, et al.
Frontiers in Oncology|October 9, 2023
Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patientsAlexander Giesen, Loïc Baekelandt, Wout Devlies, et al.
Anti-Cancer Drugs|March 20, 2002
Altered irinotecan metabolism in a patient receiving phenytoinRon H J Mathijssen, Alex Sparreboom, Herlinde Dumez, et al.
Expert Opinion on Pharmacotherapy|June 4, 2008
Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcomaPatrick Schöffski, Herlinde Dumez, Pascal Wolter, et al.
Pageof 7